The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: A review of the literature

This publication has 85 references indexed in Scilit:

• Frequency and characteristics of isolated para-aortic lymph node recurrence in patients with uterine cervical carcinoma in Japan: A multi-institutional study
  Gynecologic Oncology, 2006
• Serum vascular endothelial growth factor C (VEGF-C) as a specific biomarker for advanced cervical cancer: Relationship to insulin-like growth factor II (IGF-II), IGF binding protein 3 (IGF-BP3) and VEGF-B
  Gynecologic Oncology, 2005
• Production of CA125 by human lung cancer cell lines
  Clinical and Experimental Medicine, 2004
• Tumor Markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in Patients with Non-Small Cell Lung Cancer as an Aid in Histological Diagnosis and Prognosis
  Tumor Biology, 2003
• The clinical relevance of serum CYFRA 21-1 assay in patients with ovarian cancer
  International Journal of Gynecologic Cancer, 2001
• Can Initial Serum Cyfra 21-1, SCC Antigen, and TPA Levels in Squamous Cell Cervical Cancer Predict Lymph Node Metastases or Prognosis?
  Gynecologic Oncology, 2000
• Multiple tumour marker assays in advanced cervical cancer: Relationship to chemotherapy response and clinical outcome
  European Journal Of Cancer, 1996
• Serum Levels of Squamous Cell Carcinoma Antigen and Ovarian Carcinoma Antigen (CA 125) in Patients with Benign and Malignant Diseases of the Uterine Cervix
  Oncology, 1994
• Prognostic significance of pretreatment serum levels of squamous cell carcinoma antigen and CA 125 in cervical carcinoma
  European Journal Of Cancer, 1992
• Tumor Markers in Chronic Renal Failure and Hemodialysis Patients
  Nephron, 1991